SCHEMBL6433145

SCHEMBL6433145

COc1cccc(CN(CC(=O)O)S(=O)(=O)c2ccc3c(N(Cl)C(=N)N)cncc3c2)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DAGLA Q9Y4D2 4/20 0.47
TAS2R14 Q9NYV8 7/20 0.46
PLAU P00749 1/20 0.44
CA12 O43570 2/20 0.41
CA1 P00915 2/20 0.41
CA2 P00918 2/20 0.41
CA4 P22748 2/20 0.41
CA9 Q16790 2/20 0.41
LMNA P02545 1/20 0.41
KEAP1 Q14145 2/20 0.41
ABHD6 Q9BV23 1/20 0.41
NFE2L2 Q16236 1/20 0.41
ADAM10 O14672 1/20 0.41
MMP2 P08253 1/20 0.41
MMP9 P14780 1/20 0.41
MMP13 P45452 1/20 0.41
ADAM17 P78536 1/20 0.41
MEP1A Q16819 1/20 0.41
MEP1B Q16820 1/20 0.41
CXCR3 P49682 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6440602 0.91 KEAP1 (0.45) DAGLATAS2R14PLAULMNAKEAP1
Hydrochloric Acid SCHEMBL7371889 0.90 TAS2R14 (0.41) DAGLATAS2R14CA12CA1CA2
Hydrochloric Acid SCHEMBL6437621 0.85 PLAU (0.46) DAGLAPLAUCA12CA1CA2
Trifluoroacetic Acid SCHEMBL6435141 0.85 PLAU (0.49) DAGLAPLAUCA12CA1CA2
Trifluoroacetic Acid SCHEMBL6434437 0.84 PLAU (0.46) DAGLATAS2R14PLAULMNAMMP2
Hydrochloric Acid SCHEMBL6434570 0.84 PLAU (0.46) DAGLAPLAUCA12CA1CA2
Hydrochloric Acid SCHEMBL7366869 0.84 PLAU (0.41) DAGLAPLAUKEAP1NFE2L2MMP2
SCHEMBL7379322 0.83 DAGLA (0.45) DAGLATAS2R14PLAUCA12CA1
SCHEMBL7049621 0.82 PLAU (0.42) TAS2R14PLAUCA12CA1CA2
SCHEMBL7367639 0.81 ALDH1A1 (0.42) TAS2R14LMNAMEP1BCXCR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050026836-A1 Composition for the treatment of damaged tissue DACK KEVIN NEIL (GB) 2005-02-03 US disclosed
US-20030199440-A1 Composition for the treatment of damaged tissue PFIZER INC. 2003-10-23 US disclosed
EP-1077945-B1 ISOQUINOLINES AS UROKINASE INHIBITORS PFIZER (US) 2003-01-08 EP disclosed
EP-1242120-A2 COMBINATIONS OF GROWTH FACTORS AND I:UPA OR I:MMP FOR THE TREATMENT OF DAMAGED TISSUE Pfizer Limited (GB) 2002-09-25 EP disclosed
WO-2001049309-A2 COMBINATIONS OF GROWTH FACTORS AND I: UPA OR I: MMP FOR THE TREATMENT OF DAMAGED TISSUE PFIZER LIMITED (GB) 2001-07-12 WO disclosed
EP-1077945-A1 ISOQUINOLINES AS UROKINASE INHIBITORS PFIZER INC. (US) 2001-02-28 EP disclosed
US-6093731-A Isoquinolines PFIZER INC. 2000-07-25 US disclosed
WO-2000005214-A2 ISOQUINOLINES AS UROKINASE INHIBITORS PFIZER INC. (US) 2000-02-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030199440-A1 Composition for the treatment of damaged tissue MMP1, SERPINE1, COL14A1 DAGLA 806/4885TAS2R14 2998/4885PLAU 119/4885
US-20050026836-A1 Composition for the treatment of damaged tissue MMP1, SERPINE1, COL14A1 DAGLA 806/4885TAS2R14 2998/4885PLAU 119/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.